Mihael H. Polymeropoulos - 25 Feb 2025 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role: President and CEO, Director, Chairman of the Board
Signature: /s/ Mihael H. Polymeropoulos
Issuer symbol: VNDA
Transactions as of: 25 Feb 2025
Net transactions value: +$44,640
Form type: 4
Filing time: 25 Feb 2025, 19:38:24 UTC
Previous filing: 20 Feb 2025
Next filing: 26 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VNDA	Common Stock	Purchase	$44,640	+10,000	+0.43%	$4.46	2,331,730	25 Feb 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.445 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.445 to $4.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.